pyrroles has been researched along with Calcinosis in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (71.74) | 29.6817 |
| 2010's | 12 (26.09) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, X; Zhao, H | 1 |
| Castaños-Mollor, I; García-Rodríguez, C; Gómez, C; López, J; Parra-Izquierdo, I; San Román, JA; Sánchez Crespo, M | 1 |
| Agarwal, P; Frye, BC; May, AM; Rizzi, M; Thiel, J; Venhoff, N; Voll, RE; Wendel, S | 1 |
| Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G | 1 |
| King, A | 1 |
| Chou, DW; Guo, H; Li, Q; Uitto, J | 1 |
| Luft, FC | 1 |
| de Ceuninck, M; Trenson, S | 1 |
| Gao, X; Gu, G; Hu, W; Jin, S; Li, J; Li, Y; Wu, PH; Zhan, C; Zhang, L | 1 |
| Cawley, PJ; Otto, CM | 1 |
| Alber, HF; Bartel, T; Dichtl, W; Feuchtner, GM; Grander, W; Hintringer, F; Müller, S; Pachinger, O; Reinthaler, M; Süssenbacher, A; Ulmer, H | 1 |
| Chen, X; Liu, C; Peng, W; Qi, B; Wan, J; Yang, Q | 1 |
| Martinez, DG | 1 |
| Clementi, F; Di Luozzo, M; Luciani, G; Mango, R; Martuscelli, E; Mehta, JL; Pizzuto, F; Romeo, F; Trivisonno, A | 1 |
| Avgerinos, ED; Gerasimidis, T; Kadoglou, NP; Kakisis, JD; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Moumtzouoglou, A | 1 |
| Fan, YH; Hu, T; Jia, G; Li, H; Tao, HR; Wang, HC; Zhang, RQ | 1 |
| Dimitrow, PP; Gackowski, A; Jawień, M | 1 |
| Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Akiba, T; Nihei, H; Nitta, K | 1 |
| Jono, S; Kizu, A; Koyama, H; Nishizawa, Y; Okuno, Y; Shioi, A | 1 |
| Rajamannan, NM | 1 |
| Bonow, RH; Bonow, RO; Caira, F; Makkena, B; Rajamannan, NM; Salti, H; Spelsberg, TC; Subramaniam, M; Thennapan, S | 1 |
| Bonow, RO; Ignatiev, KI; McConnell, JP; Rajamannan, NM; Singh, RJ; Spelsberg, TC; Springett, M; Stock, SR; Stone, NJ; Subramaniam, M | 1 |
| Bloomfield, P; Boon, NA; Cowell, SJ; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Rosenhek, R | 1 |
| Arad, Y; Guerci, AD; Newstein, D; Roth, M; Spadaro, LA | 1 |
| Caira, F; Rajamannan, NM; Spelsberg, TC; Stock, SR; Subramaniam, M | 1 |
| Achenbach, S; Budde, T; Buziashvili, Y; Erbel, R; Förster, A; Friedrich, G; Henein, M; Kerkhoff, G; Knollmann, F; Kukharchuk, V; Lahiri, A; Leischik, R; Moshage, W; Schartl, M; Schmermund, A; Siffert, W; Sinitsyn, V; Steinhagen-Thiessen, E; Vogt, A; Wiedeking, B | 1 |
| Boon, NA; Burton, J; Cowell, SJ; Houslay, ES; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Antoniades, C; Stefanadis, C; Tousoulis, D | 1 |
| Akishita, M; Eto, M; Iijima, K; Kojima, T; Kozaki, K; Maemura, K; Nakano, T; Ota, H; Ouchi, Y; Senda, Y; Son, BK | 1 |
| Amrani, M; Chester, AH; Osman, L; Smolenski, RT; Yacoub, MH | 1 |
| Amrani, M; Chester, AH; Latif, N; Osman, L; Yacoub, MH | 1 |
| Erbel, R; Schmermund, A | 1 |
| Miserez, AR; Romanens, MJ | 1 |
| Bax, WH; Jukema, JW; Schutte-Bart, C; Trion, A; van der Laarse, A | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Bandios, S; Fotiadis, G; Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katinios, A; Kougias, P; Liapis, CD; Moumtzouoglou, A; Sailer, N; Vitta, I; Voliotis, K | 1 |
| Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W | 1 |
| Bonnaire, B; Bugnicourt, JM; Garcia, PY; Godefroy, O; Lefranc, M; Lepage, L | 1 |
| Arad, Y; Guerci, AD; Newstein, D; Roth, M | 1 |
| Raggi, P | 1 |
| Bakker Schut, TC; Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; Römer, TJ; van De Poll, SW; van Der Laarse, A; Volger, OL | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bonow, RO; McConnell, JP; Niekrasz, M; Rajamannan, NM; Sebo, TC; Singh, RJ; Spelsberg, TC; Springett, M; Stone, NJ; Subramaniam, M | 1 |
1 review(s) available for pyrroles and Calcinosis
| Article | Year |
|---|---|
Prevention of calcific aortic valve stenosis-fact or fiction?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2009 |
12 trial(s) available for pyrroles and Calcinosis
| Article | Year |
|---|---|
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; C-Reactive Protein; Calcinosis; Cholesterol; Disease Progression; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Tomography, X-Ray Computed | 2008 |
The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Biomarkers; Calcinosis; Down-Regulation; Drug Administration Schedule; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Poland; Pyrroles; RANK Ligand; Sclerosis; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult | 2011 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Blood Flow Velocity; Calcinosis; Cholesterol, LDL; Disease Progression; Double-Blind Method; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Failure | 2005 |
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
Topics: Aged; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Aspirin; Atorvastatin; Calcinosis; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Tomography, X-Ray Computed | 2005 |
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.
Topics: Adult; Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Tomography, Spiral Computed; Treatment Failure | 2006 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
Topics: Aged; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Calcinosis; Carotid Stenosis; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2008 |
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors | 2008 |
33 other study(ies) available for pyrroles and Calcinosis
| Article | Year |
|---|---|
Pemigatinib-Related Calcification in the Liver.
Topics: Calcinosis; Humans; Liver; Morpholines; Pyrimidines; Pyrroles | 2023 |
Calcification Induced by Type I Interferon in Human Aortic Valve Interstitial Cells Is Larger in Males and Blunted by a Janus Kinase Inhibitor.
Topics: Aortic Valve; Aortic Valve Stenosis; Apoptosis; Bone Morphogenetic Protein 2; Calcinosis; Cell Differentiation; Cells, Cultured; Cytokines; Female; Humans; Interferon Type I; Janus Kinase Inhibitors; Lipopolysaccharides; Male; NF-kappa B; Osteoblasts; Piperidines; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Sex Factors; Signal Transduction; STAT Transcription Factors; Toll-Like Receptor 4 | 2018 |
Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Topics: Calcinosis; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; MAP Kinase Kinase 4; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2019 |
Vascular disease: aortic plaque--dual therapy for a heterogeneous disease.
Topics: Aortic Diseases; Calcinosis; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Plaque, Atherosclerotic; Pyrroles | 2013 |
Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6⁻/⁻).
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Calcinosis; Calcium; Connective Tissue; Dermis; Disease Models, Animal; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mice; Mice, Knockout; Pseudoxanthoma Elasticum; Pyrroles | 2013 |
Pseudoxanthoma elasticum and statin prophylaxis.
Topics: Animals; Atorvastatin; Calcinosis; Connective Tissue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pseudoxanthoma Elasticum; Pyrroles | 2013 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calcinosis; Diagnosis, Differential; Female; Heart Neoplasms; Heart Valve Diseases; Heptanoic Acids; Humans; Hypertension; Mitral Valve; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Radiography; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
The effect of oxLDL on aortic valve calcification via the Wnt/ β-catenin signaling pathway: an important molecular mechanism.
Topics: Animals; Aortic Valve; Apoptosis; Atorvastatin; Bicuspid Aortic Valve Disease; Blotting, Western; Calcinosis; Cells, Cultured; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Myofibroblasts; Pyrroles; Swine; Wnt Signaling Pathway | 2015 |
Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.
Topics: Animals; Aortic Diseases; Atorvastatin; Blood Pressure; Calcinosis; Heptanoic Acids; Hypertension; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Warfarin | 2008 |
Binder wars.
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke | 2008 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Necrosis; Pilot Projects; Pioglitazone; Prospective Studies; Pyrroles; Registries; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis.
Topics: Aged; Angioplasty; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Carotid Stenosis; Combined Modality Therapy; Down-Regulation; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Atorvastatin reduces calcification in rat arteries and vascular smooth muscle cells.
Topics: Animals; Aorta, Abdominal; Atorvastatin; Calcinosis; Calcium; Cells, Cultured; Drug Combinations; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Injections, Subcutaneous; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; Rats; Rats, Sprague-Dawley; Thoracic Arteries; Vitamin D; Warfarin | 2010 |
Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Calcinosis; Disease Progression; Drug Therapy, Combination; Epichlorohydrin; Heptanoic Acids; Humans; Imidazoles; Prospective Studies; Pyrroles; Renal Dialysis; Resins, Synthetic | 2004 |
Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.
Topics: Alkaline Phosphatase; Atorvastatin; Calcinosis; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Sesquiterpenes | 2004 |
Is it time for medical therapy for aortic valve disease?
Topics: Aged; Aged, 80 and over; Animals; Aortic Valve Stenosis; Atorvastatin; Biopsy, Needle; Calcinosis; Controlled Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunohistochemistry; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Matrix; Calcinosis; Cell Division; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Mitral Valve; Pyrroles; Rabbits | 2005 |
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Blotting, Western; C-Reactive Protein; Calcinosis; Cholesterol; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rabbits; Tomography, X-Ray Computed | 2005 |
Statins for aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Calcinosis; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.
Topics: Animals; Animals, Inbred Strains; Aortic Valve Stenosis; Atorvastatin; beta Catenin; Calcinosis; Cell Division; Cells, Cultured; Cholesterol, Dietary; Diet, Atherogenic; Fibroblasts; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; LDL-Receptor Related Proteins; Lipoproteins, LDL; Low Density Lipoprotein Receptor-Related Protein-5; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Ossification, Heterotopic; Osteopontin; Pyrroles; Rabbits; Sialoglycoproteins; Sus scrofa | 2005 |
Statins and antioxidant vitamins: should co-administration be avoided?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Calcinosis; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Vitamin E | 2006 |
Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway.
Topics: Aorta; Apoptosis; Atorvastatin; Axl Receptor Tyrosine Kinase; Calcinosis; DNA Primers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Muscle, Smooth, Vascular; Oncogene Proteins; Phosphates; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2006 |
A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphatases; Adenosine Triphosphate; Aged; Alkaline Phosphatase; Aortic Valve; Aortic Valve Stenosis; Apyrase; Atorvastatin; Biomarkers; Calcinosis; Cell Differentiation; Cells, Cultured; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Middle Aged; Osteoblasts; Pyrroles; Receptors, Purinergic P2; Second Messenger Systems | 2006 |
Role of human valve interstitial cells in valve calcification and their response to atorvastatin.
Topics: Aged; Alkaline Phosphatase; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcinosis; Cell Differentiation; Cells, Cultured; Connective Tissue Cells; Culture Media; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Osteoblasts; Osteocalcin; Pyrroles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta3 | 2006 |
Letter by Schmermund and Erbel regarding article, "Coronary artery calcium: should we rely on this surrogate marker?".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium; Coronary Artery Disease; Coronary Vessels; Disease Progression; Heptanoic Acids; Humans; Predictive Value of Tests; Prognosis; Pyrroles; Risk Factors | 2006 |
Letter by Romanens and Miserez regarding article, "Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sample Size | 2006 |
Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination.
Topics: Amlodipine; Animals; Animals, Newborn; Aorta; Apoptosis; Ascorbic Acid; Atorvastatin; Calcinosis; Calcium; Cell Proliferation; Cell Separation; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Space; Heptanoic Acids; Muscle, Smooth, Vascular; Phosphates; Pyrroles; Rats; Rats, Wistar | 2008 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvastatin; Calcinosis; Heptanoic Acids; Humans; Intracranial Embolism; Male; Pyrroles; Stroke; Tomography, X-Ray Computed | 2008 |
Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification.
Topics: Aged; Antioxidants; Atorvastatin; Calcinosis; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2001 |
The use of electron-beam computed tomography as a tool for primary prevention.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Mass Screening; Middle Aged; Myocardial Infarction; Pyrroles; Tomography, X-Ray Computed | 2001 |
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcinosis; Cholesterol; Diet, Atherogenic; Disease Progression; Female; Heptanoic Acids; Male; Mice; Mice, Transgenic; Pyrroles; Reproducibility of Results; Spectrum Analysis, Raman; Treatment Outcome | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.
Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Cell Division; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Macrophages; Male; Microscopy, Immunoelectron; Osteoblasts; Osteopontin; Proliferating Cell Nuclear Antigen; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sialoglycoproteins | 2002 |